Key Drivers
- Cash Cushion
- Revenue Gap
- Cash Burn
AIAI Summary
BLTE has shifted from a “promising data” biotech to a near-term FDA execution story, with tinlarebant's rolling NDA and a ~$773M cash cushion materially improving the setup, but the stock remains a high-stakes single-asset bet where any approval delay or setback could trigger sharp re-rating risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Revenue Gap
- •Cash Burn
BLTE has an exceptionally strong cash-rich balance sheet, but with no revenue, persistent losses, and ongoing free cash flow burn, the stock looks financially safe for now yet fundamentally expensive.
Price Behavior
Key Price Behavior Insights:
- •Mid-June rebound
- •Late pullback
- •Range resistance
Over the last month, BLTE is still modestly constructive after rebounding from mid-June lows, but the late-June drop from near $155 to $146.63 leaves the short-term bullish case fragile until $142–$143 support holds and $155 is reclaimed.
Sharp two-day pullback from $153.99 on 2026-06-30 to $146.63 on 2026-07-02
Sentiment & News
Key News Insights:
- •NDA milestone
- •Stargardt focus
- •Regulatory progress
Belite Bio completed the rolling NDA submission for tinlarebant to the FDA, marking a key regulatory step toward potential approval in Stargardt disease type 1
This is a constructive development that improves Belite Bio's regulatory visibility and supports the investment case for tinlarebant in a high-unmet-need rare disease
Similar Companies in Healthcare
Other companies in the same sector with AI ratings